Filtered By:
Source: Herz
Condition: Bleeding
Drug: Warfarin
This page shows you your search results in order of date.
Order by Relevance | Date
Total 2 results found since Jan 2013.
New oral anticoagulants for nonvalvular atrial fibrillation with peripheral artery disease: a meta-analysis.
CONCLUSION: The findings show that NOACs are effective and safe for preventing stroke/SE in patients with both NVAF and PAD.
PMID: 32728781 [PubMed - as supplied by publisher]
Source: Herz - August 1, 2020 Category: Cardiology Tags: Herz Source Type: research
Anticoagulant plus antiplatelet therapy for atrial fibrillation : Cost-utility of combination therapy with non-vitamin K oral anticoagulants vs. warfarin.
CONCLUSION: The derived ICER was 13,168.50 € per QALY, consistent with NOACs being cost-effective vs. warfarin when anticoagulation is used with antiplatelet agents. Nevertheless, country-, practice-, and patient-related factors influence the ICER. Our cost-utility calculation should be used a starting point for decision-making.
PMID: 30209519 [PubMed - as supplied by publisher]
Source: Herz - September 15, 2018 Category: Cardiology Tags: Herz Source Type: research
